Cargando…

Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler

BACKGROUND: Intramuscular (L-)epinephrine is used as self-medication for serious hypersensitivity reactions. Inhalative administration has the theoretical advantage of a more rapid absorption and better controllability. OBJECTIVES: The current trial was conducted to explore pharmacokinetics and phar...

Descripción completa

Detalles Bibliográficos
Autores principales: Breuer, C., Wachall, B., Gerbeth, K., Abdel-Tawab, M., Fuhr, U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651817/
https://www.ncbi.nlm.nih.gov/pubmed/23292159
http://dx.doi.org/10.1007/s00228-012-1465-5
_version_ 1782269240584175616
author Breuer, C.
Wachall, B.
Gerbeth, K.
Abdel-Tawab, M.
Fuhr, U.
author_facet Breuer, C.
Wachall, B.
Gerbeth, K.
Abdel-Tawab, M.
Fuhr, U.
author_sort Breuer, C.
collection PubMed
description BACKGROUND: Intramuscular (L-)epinephrine is used as self-medication for serious hypersensitivity reactions. Inhalative administration has the theoretical advantage of a more rapid absorption and better controllability. OBJECTIVES: The current trial was conducted to explore pharmacokinetics and pharmacodynamics of two nebulized inhalative epinephrine doses (4 mg and 8 mg in aqueous solution) using a mobile pocket inhaler relative to intramuscular administration (0.3 mg) and placebo. METHODS: This randomized, open-label, change-over pilot study involved eight young healthy men and women. Noncompartmental pharmacokinetic and pharmacodynamic parameters were calculated from epinephrine plasma concentrations and hemodynamic parameters. RESULTS: Mean exposure to epinephrine decreased from the 8 mg dose to the 4 mg inhalative dose, and further with the 0.3 mg intramuscular dose, with active treatments showing significantly higher concentrations than placebo (geometric mean area under the curve AUC(0-t(last)) values: 282, 236, 204 and 81.6 hr*ng/L). Maximal concentrations were reached within approximately 15 min for all active treatments. Epinephrine effects for inhalative administrations on heart rates were significantly higher than those for the intramuscular or placebo administration, while no excessive effects occurred. Pronounced overall variability prohibited a definite assessment of relative bioavailability between treatments. However, results indicated that epinephrine concentrations obtained following the 8 mg inhalative dose were not inferior to those after 0.3 mg i.m. CONCLUSIONS: A relevant fraction of moist inhalation epinephrine doses is absorbed and mediates systemic effects. This suggests that administration of epinephrine via a suitable pocket inhaler device may be beneficial in ambulatory emergency treatment of systemic hypersensitivity reactions. EudraCT number: 2010-021493-11 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00228-012-1465-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-3651817
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-36518172013-05-13 Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler Breuer, C. Wachall, B. Gerbeth, K. Abdel-Tawab, M. Fuhr, U. Eur J Clin Pharmacol Pharmacokinetics and Disposition BACKGROUND: Intramuscular (L-)epinephrine is used as self-medication for serious hypersensitivity reactions. Inhalative administration has the theoretical advantage of a more rapid absorption and better controllability. OBJECTIVES: The current trial was conducted to explore pharmacokinetics and pharmacodynamics of two nebulized inhalative epinephrine doses (4 mg and 8 mg in aqueous solution) using a mobile pocket inhaler relative to intramuscular administration (0.3 mg) and placebo. METHODS: This randomized, open-label, change-over pilot study involved eight young healthy men and women. Noncompartmental pharmacokinetic and pharmacodynamic parameters were calculated from epinephrine plasma concentrations and hemodynamic parameters. RESULTS: Mean exposure to epinephrine decreased from the 8 mg dose to the 4 mg inhalative dose, and further with the 0.3 mg intramuscular dose, with active treatments showing significantly higher concentrations than placebo (geometric mean area under the curve AUC(0-t(last)) values: 282, 236, 204 and 81.6 hr*ng/L). Maximal concentrations were reached within approximately 15 min for all active treatments. Epinephrine effects for inhalative administrations on heart rates were significantly higher than those for the intramuscular or placebo administration, while no excessive effects occurred. Pronounced overall variability prohibited a definite assessment of relative bioavailability between treatments. However, results indicated that epinephrine concentrations obtained following the 8 mg inhalative dose were not inferior to those after 0.3 mg i.m. CONCLUSIONS: A relevant fraction of moist inhalation epinephrine doses is absorbed and mediates systemic effects. This suggests that administration of epinephrine via a suitable pocket inhaler device may be beneficial in ambulatory emergency treatment of systemic hypersensitivity reactions. EudraCT number: 2010-021493-11 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00228-012-1465-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2013-01-05 2013 /pmc/articles/PMC3651817/ /pubmed/23292159 http://dx.doi.org/10.1007/s00228-012-1465-5 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by-nc/2.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Pharmacokinetics and Disposition
Breuer, C.
Wachall, B.
Gerbeth, K.
Abdel-Tawab, M.
Fuhr, U.
Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler
title Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler
title_full Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler
title_fullStr Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler
title_full_unstemmed Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler
title_short Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler
title_sort pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler
topic Pharmacokinetics and Disposition
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651817/
https://www.ncbi.nlm.nih.gov/pubmed/23292159
http://dx.doi.org/10.1007/s00228-012-1465-5
work_keys_str_mv AT breuerc pharmacokineticsandpharmacodynamicsofmoistinhalationepinephrineusingamobileinhaler
AT wachallb pharmacokineticsandpharmacodynamicsofmoistinhalationepinephrineusingamobileinhaler
AT gerbethk pharmacokineticsandpharmacodynamicsofmoistinhalationepinephrineusingamobileinhaler
AT abdeltawabm pharmacokineticsandpharmacodynamicsofmoistinhalationepinephrineusingamobileinhaler
AT fuhru pharmacokineticsandpharmacodynamicsofmoistinhalationepinephrineusingamobileinhaler